Last updated 2026-07-26
TL;DR
The best human evidence for CJC-1295 is a single 2006 phase 1 trial showing sustained GH and IGF-1 increases after weeks of dosing. There's no published data on ipamorelin pairing, fat loss, muscle gain, or long-term safety in humans. Everything past that one trial (stacking protocols, body recomposition claims, anti-aging effects) comes from forums and marketing, not peer-reviewed research.
What does the actual research on CJC-1295 show?
The core human data set is small: one phase 1 trial, published in 2006 in Molecular and Cellular Endocrinology, tested CJC-1295 (the DAC version) in 40 healthy adults. Single doses of 30, 60, 100, or 200 mcg/kg raised mean plasma GH by 2 to 10 fold, and a single 60 mcg/kg dose kept GH elevated for 6 or more days [1]. A multi-dose arm giving 30 or 60 mcg/kg every 7 to 14 days for up to 6 weeks raised mean IGF-1 levels by 1.5 to 3 times baseline, and the effect held steady across the dosing period without obvious tachyphylaxis [1]. That's it. That's the trial almost every claim about CJC-1295 traces back to, directly or through several layers of paraphrase. It's a real, peer-reviewed, industry-funded (ConjuChem, the company that developed the DAC technology) study, and the findings are legitimate as far as they go: GH and IGF-1 went up, and stayed up longer than you'd expect from a normal GHRH peptide. But it's a pharmacokinetic and short-term safety study in healthy volunteers, not a trial measuring muscle mass, fat loss, athletic performance, sleep quality, or skin appearance. Nobody has published a randomized controlled trial answering 'does CJC-1295 change body composition in humans,' full stop. Separately, the parent compound class, modified GHRH(1-29) analogues, has decades of legitimate research behind it establishing the mechanism (GHRH receptor agonism on pituitary somatotrophs). CJC-1295 is essentially a GHRH(1-29) analogue with two changes: amino acid substitutions to resist enzymatic breakdown, and, in the DAC version, a chemical handle that binds serum albumin to extend half-life [1][2]. The mechanism is well understood. The downstream human outcomes reported in bodybuilding and anti-aging spaces are not backed by the same quality of evidence.
What is CJC-1295 and how does it work?
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH), engineered to survive longer in the body than natural GHRH, which has a half-life of only a few minutes [2]. It binds the GHRH receptor on the pituitary gland and prompts somatotroph cells to release growth hormone in a pulse, similar to the body's own signal, rather than flooding GH continuously [1]. The modifications matter. Natural GHRH is broken down almost instantly by an enzyme called dipeptidyl peptidase-4 (DPP-4) and cleared by the kidneys. CJC-1295 swaps out the amino acids DPP-4 targets, which alone extends functional half-life. The 'DAC' version adds a Drug Affinity Complex, a maleimide group that forms a covalent bond with albumin in the bloodstream, turning the peptide into something the body clears far more slowly [2]. That's the whole trick. It's not a growth hormone itself. It's an upstream signal that asks the pituitary to make more of its own GH, which is the theoretical reason it's marketed as more 'physiologic' than injecting synthetic HGH directly. Whether that theoretical advantage translates into a meaningfully different or safer outcome for a healthy adult using it off-label has not been tested head to head in a published trial.
What's the difference between CJC-1295 with DAC and without DAC?
This is the single most important distinction in the whole topic, and it's routinely blurred in retail listings. CJC-1295 with DAC is the compound from the 2006 trial: half-life of roughly 6 to 8 days in that study, dosed every 7 to 14 days, producing a sustained, flattened elevation in GH and IGF-1 over weeks [1]. This is the version with actual published human pharmacokinetic data behind it. 'CJC-1295 without DAC' is a different, shorter-acting molecule, missing the albumin-binding tail. It's frequently sold under that same product name but its behavior is closer to a plain modified GHRH with a half-life measured in minutes to roughly half an hour, not days. Some vendors and forum sources call this version 'Mod GRF (1-29)' or 'tesamorelin-like,' which is more accurate, since without the DAC tag it isn't the molecule ConjuChem tested. The no-DAC version is typically dosed once or more daily on the logic of mimicking a natural GH pulse, an idea borrowed from how growth hormone releasing peptides and GHRH are used together in that shorter-acting dosing pattern, but this specific dosing pattern for the no-DAC molecule has not been validated in a published trial the way the DAC version has. In short: only one of these two products has a named, peer-reviewed pharmacokinetic study behind it, and it's the DAC version. If a listing doesn't specify which one you're looking at, that's a real problem, not a technicality. For a full dosing breakdown by version, see cjc 1295 dosage and the cjc-1295 dac dosage calculator.
How much does CJC-1295 raise GH and IGF-1 levels?
| Single dose raises GH 2-10x for 6+ days (DAC version) | Published, phase 1 trial, n=40 [1] |
|---|---|
| Repeated dosing raises IGF-1 to 1.5-3x baseline over 6 weeks | Published, same trial [1] |
| No-DAC version needs daily/multiple daily dosing to sustain effect | Mechanistically plausible from half-life, not directly trial-tested at that cadence |
| Increases lean mass / reduces fat mass in healthy adults | Not tested in a published human trial |
| Improves sleep quality, skin, recovery | Not tested in a published human trial |
| Safe and effective long-term (months to years) | Not tested; longest published dosing window is 6 weeks [1] |
In the 2006 trial, a single 60 mcg/kg dose of CJC-1295 with DAC raised mean plasma GH roughly 2 to 10 fold depending on the dose tested, with the effect persisting for at least 6 days after one injection [1]. In the repeated-dosing arm, subjects getting 30 or 60 mcg/kg once every 1 to 2 weeks for 6 weeks saw mean IGF-1 levels rise to roughly 1.5 to 3 times baseline and stay elevated in that range throughout the study period [1]. Here's the honest caveat: those are group means from a small phase 1 trial (n=40 total, split across multiple dose arms), not a distribution you can promise any individual will land in. Phase 1 trials are built to establish safety and rough dose-response, not to nail down a reliable population-level effect size. There is no larger confirmatory trial published since 2006 that reproduces these numbers in a bigger sample. For comparison, here's how that trial's findings stack up against what's actually published, versus what's commonly claimed online: | Claim | Status |
Does CJC-1295 build muscle or burn fat?
Nobody has published a trial answering this directly. The 2006 study measured GH and IGF-1 blood levels and basic safety parameters, not lean mass, fat mass, strength, or performance outcomes [1]. Any claim you see about CJC-1295 packing on muscle or stripping fat is extrapolated from what elevated GH and IGF-1 generally do in other contexts, not from a study of CJC-1295 itself doing those things. There is separate, better-established science on growth hormone's general role in body composition. Reviews and endocrine society guidance describe GH's effects on lipolysis and protein synthesis in adults with diagnosed GH deficiency [3]. That's a different population and a different intervention (recombinant human GH, not a GHRH analogue), and the effect size in a GH-deficient adult replacing a hormone they're missing is not a stand-in for what happens in someone whose pituitary already works normally. If body recomposition is the actual goal, the honest answer is: there's no published trial showing CJC-1295 delivers it, and the closest real data (GH replacement in deficient adults) doesn't map cleanly onto healthy off-label users. That gap between mechanism and outcome is exactly where forum lore fills in the blanks with confidence the data doesn't support.
Why is CJC-1295 usually paired with ipamorelin?
The rationale is mechanistic, not clinical outcome data. CJC-1295 is a GHRH receptor agonist; ipamorelin is a ghrelin receptor agonist (a growth hormone releasing peptide, or GHRP). These are two different receptor systems that both converge on GH release from the pituitary, and in principle, hitting both at once produces a bigger GH pulse than either alone, because they act through non-overlapping pathways. This combined-effect idea has support from older research on GHRH combined with GHRP-class secretagogues in general, showing combined administration can produce a greater acute GH pulse than either compound alone in some human studies of the drug classes separately. But there is no published trial testing the specific combination of CJC-1295 and ipamorelin together, at any dose, in humans. The pairing is a logical extension of two separate, real mechanisms, not a studied combination with its own safety or efficacy data. Ipamorelin itself is comparatively selective, meaning it prompts GH release without strongly triggering cortisol or prolactin release the way some older GHRPs (like GHRP-6) do, based on receptor-binding studies of ipamorelin as a ghrelin mimetic. That selectivity is part of why it's the GHRP most often chosen for pairing over older, less selective options. But 'more selective at the receptor' is not the same claim as 'the combination has been proven safe or effective in a trial,' and treating it that way overstates what's known.
How long does it take to see results from CJC-1295?
Based on the only real pharmacokinetic data available, GH elevation from a single DAC dose starts working within the injection window and persists for at least 6 days [1]. IGF-1, which is the more clinically meaningful marker since it reflects sustained GH action rather than a single pulse, rose over the course of weekly to biweekly dosing and stayed elevated through the 6-week study period [1]. What that means practically: if you're tracking IGF-1 via bloodwork (the only objective, published-precedent way to know the compound is doing something), a reasonable expectation based on the trial's timeline is some detectable rise within 1 to 2 weeks of consistent dosing, continuing to build over the following weeks. What it does not tell you is when, or whether, someone would notice subjective changes like better sleep, visible body composition change, or improved recovery, because the trial didn't measure those things. Any specific week-by-week 'you'll notice X by week 4' timeline you see elsewhere is not sourced from the clinical literature; it's anecdote, and anecdote from anonymous forum posts at that.
What are the side effects and safety concerns with CJC-1295?
In the 2006 trial, reported adverse events were consistent with what you'd expect from GH-axis stimulation: injection site reactions, flushing, and some reports of headache were noted among the safety findings [1]. The trial was not large or long enough to detect rarer or longer-latency risks, and no published trial has followed users for the months or years that off-label users often actually dose for. There are mechanistic safety concerns worth taking seriously even without long-term trial data. Sustained IGF-1 elevation is a biological pathway of interest in oncology research generally, and elevated IGF-1 has been studied as a risk marker in some cancer epidemiology literature, though causation in the context of exogenous GHRH peptide use specifically has not been established. Water retention, joint discomfort, and insulin sensitivity changes are commonly reported with GH-axis stimulation broadly and are biologically plausible with any compound that meaningfully raises IGF-1, whether or not they've been specifically quantified for CJC-1295 in a trial. For the fuller side effect picture including what's mechanism-based versus anecdotal, see cjc 1295 side effects. If you're on any medication or have a personal or family history of hormone-sensitive conditions, that's a conversation for a doctor before starting, not a forum thread.
Is CJC-1295 legal, and is it FDA-approved for any use?
CJC-1295 is not FDA-approved for any human use, and it is not the same regulatory category as an approved drug. It's most commonly sold as a 'research chemical,' which is a legal label meaning it isn't approved or labeled for human consumption, not a claim about safety. Compounding pharmacies in the US operate under a different framework: under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy can compound a preparation for an individual patient with a valid prescription, using bulk drug substances that meet applicable standards [4]. Whether a specific peptide is legally compoundable depends on its status on FDA's bulk substances lists and evolving agency guidance, and that status can change; it is not a blanket green light for any peptide sold online. This is the practical reason 'provider-reviewed' sourcing matters more than price. A route where a clinician reviews your history and a prescription is filled by a licensed pharmacy is a meaningfully different legal and quality picture than an unregulated peptide vendor with no prescriber involved. CJC-1295 Co's site is built around that provider-reviewed model rather than direct-to-consumer vials; see cjc 1295 for sale for how sourcing quality is evaluated.
What dosing protocols have actually been studied?
The only dosing schedule with a name attached to real published data is the 2006 trial's: single doses of 30, 60, 100, and 200 mcg/kg, and repeated dosing of 30 or 60 mcg/kg every 7 to 14 days for 6 weeks, all with the DAC version [1]. Those are body-weight-scaled research doses in a clinical trial setting, not consumer-facing 'start with 100 mcg' type protocols you see in dosing guides. Everything more granular you'll find online (2 mg per week split into two shots, daily 100 mcg no-DAC dosing before bed, specific cycle lengths of 8, 12, or 16 weeks) comes from user reports and vendor guidance layered on top of the trial's dose range and general half-life logic, not from a second clinical trial replicating those specific protocols. That doesn't automatically make them wrong, but it does mean the specific number on a bodybuilding forum has a much thinner evidence base than the number from the 2006 paper. For a full breakdown of DAC versus no-DAC dosing conventions and how they map (loosely) back to the trial data, cjc 1295 dosage walks through the practical side, and the cjc-1295 dac dosage calculator converts weight-based research doses into common vial concentrations.
How does CJC-1295 compare to other growth hormone secretagogues?
Tesamorelin is the closest real comparison point, because it's the one GHRH analogue in this general family that actually went through full FDA approval, for HIV-associated lipodystrophy, based on phase 3 trials showing reductions in visceral adipose tissue [5]. That approval pathway required large randomized trials with body composition as a primary endpoint, exactly the kind of evidence CJC-1295 does not have. Sermorelin is an earlier, shorter-acting GHRH(1-29) fragment with its own FDA history (approved and later discontinued as a branded product, Geref, though the underlying peptide is still used clinically and via compounding) [6]. It requires more frequent dosing than CJC-1295 DAC because it lacks any half-life extension technology. MK-677 (ibutamoren) is an oral ghrelin receptor agonist, not a GHRH analogue, so it works through the same general pathway as ipamorelin rather than the same pathway as CJC-1295, and it has its own separate trial history in aging and post-surgical populations. The honest summary: tesamorelin has the strongest clinical trial pedigree of anything in this comparison set, specifically because it was taken through FDA approval. CJC-1295 has one solid phase 1 trial and a large gap after that. Sermorelin has the longest clinical history of any GHRH-class peptide but weaker pharmacokinetics than the DAC version of CJC-1295.
What questions does the research still leave unanswered?
A short, honest list: nobody has published a trial on CJC-1295 combined with ipamorelin. Nobody has published body composition, strength, or performance outcomes for CJC-1295 alone in healthy adults. Nobody has followed users for more than 6 weeks in a controlled setting, so anything claimed about 6-month or multi-year use, cycling strategies, or long-term IGF-1 safety is extrapolation, not data. There's also no published trial specifically on the no-DAC version's pharmacokinetics at the doses and frequencies commonly sold, meaning a big share of real-world protocols are running on inference from the DAC trial and general GHRH biology, not on a study of the actual product being used. If you're evaluating a claim about CJC-1295, the useful filter is simple: does this trace back to the 2006 Molecular and Cellular Endocrinology trial, to general GH/GHRH biology research, or to an anonymous forum post? Two of those three are worth something. For the mechanism deep-dive and how it maps to the DAC molecule specifically, cjc 1295 with dac covers the pharmacology in more depth, and cjc 1295 is the general starting reference for the compound.
Frequently asked questions
Is there a published clinical trial on CJC-1295 in humans?
Yes, one phase 1 trial published in 2006 in Molecular and Cellular Endocrinology, testing single and repeated doses of CJC-1295 with DAC in 40 healthy adults, measuring GH and IGF-1 response and basic safety over up to 6 weeks. It's the primary human data source almost every other claim about the compound traces back to.
What's the difference between CJC-1295 and CJC-1295 with DAC?
'CJC-1295 with DAC' is the long-acting version with an albumin-binding tail, half-life of roughly 6-8 days, tested in the 2006 trial. Products labeled 'CJC-1295 without DAC' are a different, shorter-acting molecule with a half-life of minutes, often more accurately called Mod GRF (1-29), lacking the same published pharmacokinetic study.
Does CJC-1295 actually increase growth hormone levels?
In the one published trial, yes: a single 60 mcg/kg dose of the DAC version raised mean GH 2 to 10 fold and kept it elevated for at least 6 days, and repeated dosing over 6 weeks raised mean IGF-1 to roughly 1.5 to 3 times baseline. That's group-average trial data, not a guarantee for any individual.
Is CJC-1295 FDA-approved?
No. CJC-1295 has no FDA approval for any indication and is typically sold as a research chemical. A related peptide in the same broad class, tesamorelin, is FDA-approved for a specific condition (HIV-associated lipodystrophy), but that approval doesn't extend to CJC-1295.
Why do people combine CJC-1295 with ipamorelin?
CJC-1295 activates the GHRH receptor while ipamorelin activates the ghrelin receptor, two different pathways that both trigger pituitary GH release. The rationale is mechanistic, combining receptor targets, similar to older studies combining GHRH with GHRP-class peptides generally. No published trial has tested this exact CJC-1295 plus ipamorelin combination directly.
How long before you see results from CJC-1295?
The 2006 trial found GH elevation within the dosing window and IGF-1 rising over 1 to 2 weeks of repeated dosing, continuing through 6 weeks of observation. Subjective changes like body composition or sleep were not measured in that trial, so there's no published timeline for those outcomes.
Does CJC-1295 help with fat loss or building muscle?
No published human trial has tested CJC-1295 for fat loss or muscle gain specifically. The 2006 trial measured GH and IGF-1 blood levels only. Claims about body recomposition are extrapolated from general GH biology in GH-deficient patients, not from a study of CJC-1295 producing those outcomes.
What are the known side effects of CJC-1295?
The 2006 trial reported injection site reactions and effects consistent with GH-axis stimulation among its safety findings. Because the trial only ran 6 weeks, longer-term risks from sustained IGF-1 elevation, including plausible concerns raised in general oncology and metabolic literature, have not been directly studied for this compound.
Can you legally buy CJC-1295 from a compounding pharmacy?
It depends on current FDA bulk drug substance status and whether a licensed prescriber issues a valid prescription under Section 503A of the FD&C Act. This differs by state and can change over time, which is why provider-reviewed sourcing with pharmacy fulfillment is a materially different legal picture than an unregulated peptide vendor.
How does CJC-1295 compare to tesamorelin or sermorelin?
Tesamorelin has full FDA approval backed by phase 3 trials with body composition endpoints, the strongest evidence base of the three. Sermorelin has the longest clinical history but a much shorter half-life. CJC-1295 (DAC) has one solid phase 1 trial and a long half-life, but no approval and no body composition trials.
What dose of CJC-1295 was used in clinical research?
The 2006 trial tested single doses of 30, 60, 100, and 200 mcg/kg, and repeated 30 or 60 mcg/kg doses every 7 to 14 days for 6 weeks, all using the DAC version, in a body-weight-scaled clinical trial format, not the flat mg-per-week amounts common in consumer dosing guides.
Is CJC-1295 the same as HGH?
No. CJC-1295 is a GHRH analogue that signals the pituitary to release its own growth hormone, whereas HGH (recombinant human growth hormone) is the hormone itself, injected directly. The two work through different points in the same axis and are regulated and studied separately.
Sources
- Teichman et al., Molecular and Cellular Endocrinology, 2006: Phase 1 trial data on CJC-1295 with DAC: GH and IGF-1 response, dosing, and half-life in 40 healthy adults
- PubChem, CJC-1295 compound summary: Molecular structure and DPP-4 resistance/albumin-binding mechanism of CJC-1295
- Endocrine Society, Clinical Practice Guideline on GH Deficiency in Adults: GH's established role in body composition in adults with diagnosed GH deficiency
- FDA, Section 503A of the Federal Food, Drug, and Cosmetic Act: Legal framework for pharmacy compounding of drug substances for individual patients
- FDA, Egrifta (tesamorelin) approval and label: Tesamorelin's FDA approval for HIV-associated lipodystrophy based on phase 3 trials
- FDA, Geref (sermorelin) drug approval history: Sermorelin's regulatory history as an approved and later discontinued GHRH(1-29) product